MedTrace Logo

Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

NCT00089713 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2010-02-08

No results posted yet for this study

Summary

This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).

Conditions

Interventions

DRUG

alagebrium chloride (ALT-711)

Sponsors & Collaborators

  • Synvista Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Milan Kovacevic, MD, PhD · Synvista Therapeutics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089713 on ClinicalTrials.gov